Clinical trial · no report yet · Phase 3
AMBASSADOR
Testing MK-3475 (Pembrolizumab) After Surgery for Localized Muscle-Invasive Bladder Cancer and Locally Advanced Urothelial Cancer
- NCT03244384 ↗
- Active not recruiting
- National Cancer Institute (NCI)
- 4 commentary sources found
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built. Commentary is thin so far, so the report would be short.
| Channel | Found | |
|---|---|---|
| X threads | 4 |
The trial
ClinicalTrials.gov- Official title
- Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
- Phase
- Phase 3
- Status
- Active not recruiting
- Conditions
- Localized Renal Pelvis and Ureter Urothelial Carcinoma; Locally Advanced Bladder Urothelial Carcinoma; Locally Advanced Renal Pelvis and Ureter Urothelial Carcinoma; Locally Advanced Ureter Urothelial Carcinoma; Locally Advanced Urothelial Carcinoma; Stage II Bladder Urothelial Carcinoma AJCC v6 and v7; Stage II Renal Pelvis and Ureter Cancer AJCC v7; Stage II Ureter Cancer AJCC v7; Stage III Bladder Urothelial Carcinoma AJCC v6 and v7; Stage III Renal Pelvis and Ureter Cancer AJCC v7; Stage III Ureter Cancer AJCC v7
- Interventions
- Biospecimen Collection; Clinical Observation; Computed Tomography; CT Urography; Cystoscopy; Magnetic Resonance Imaging; Pembrolizumab; Pharmacological Study; Quality-of-Life Assessment; Questionnaire Administration
- Arms
- Arm A (pembrolizumab) · Experimental
- Arm B (observation) · Active comparator
- Enrollment
- 739 (estimated)
- Primary outcomes
- Overall survival
- Disease-free survival
- Sponsor
- National Cancer Institute (NCI)
- Start
- Nov 3, 2017
- Primary completion
- Oct 31, 2026 (estimated)
- Results posted
- No
- Registry record
- NCT03244384 · updated Oct 1, 2026
Publications
linked from the registry- Apolo AB, Ballman KV, Sonpavde G, Berg S, Kim WY, Parikh R, Teo MY, Sweis RF, Geynisman DM, Grivas P, Chatta G, Reichert ZR, Kim JW, Bilen MA, McGregor B, Singh P, Tripathi A, Cole S, Simon N, Niglio S, Ley L, Cordes L, Srinivas S, Huang J, Odegaard M, Watt C, Petrylak D, Hoffman-Censits J, Wen Y, Hahn O, Mitchell C, Tan A, Streicher H, Sharon E, Moon H, Woods M, Halabi S, Perez Burbano G, Morris MJ, Rosenberg JE. Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma. N Engl J Med. 2025 Jan 2;392(1):45-55. doi: 10.1056/NEJMoa2401726. Epub 2024 Sep 15. PubMed 39282902